Syphilis Testing Market size to hit $1.05 Billion by 2035 | Top companies include Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Roche) (Switzerland), Siemens Healthineers AG (Germany), bioMérieux SA (France), Thermo Fisher Scientific Inc. (U.S.

Market Outlook and Forecast

The syphilis testing market is undergoing rapid transformation as rising infection rates, expanded screening mandates, and advancements in diagnostic accuracy continue to reshape global demand. The market was valued at USD 611.7 million in 2025 and is expected to reach USD 1.05 billion by 2035, reflecting a significant shift toward early-stage diagnosis, automation of laboratory workflows, and wider adoption of dual-testing methodologies. With accelerating demand across both public health systems and specialized diagnostic laboratories, the market is positioned for strong momentum over the coming decade, supported by a 38% CAGR from 2026 to 2035.

➤ Request Free Sample PDF Report @ https://www.researchnester.com/sample-request-8073

Regional Performance Highlights

North America leads the global Syphilis Testing Market, projected to account for 38% of total revenue by 2035. The region's leadership is supported by the rising prevalence of congenital syphilis, improved reimbursement for STI screening, and accelerated adoption of rapid treponemal/non-treponemal tests in both clinical and community settings. The U.S. has seen a notable surge in public health funding aimed at expanding syphilis surveillance and laboratory capacity.

Europe represents a substantial market driven by strong national initiatives, routine antenatal screening programs, and well-regulated diagnostic pathways. Countries such as Germany, France, Spain, and the U.K. maintain high adoption of laboratory-based and point-of-care syphilis diagnostics, supported by standardized testing algorithms and growing investments in STI prevention programs.

The Asia Pacific region is rapidly emerging with increasing burden of sexually transmitted infections, expanding healthcare access, and accelerated modernization of diagnostic laboratories. Markets such as China, India, Thailand, Philippines, and Indonesia are investing heavily in dual HIV/syphilis rapid tests and automated analyzers for high-throughput screening. Growing public-private collaborations are further boosting market penetration of affordable diagnostic solutions.

➤ Gain access to expanded insights on competitive strategies, market size, and regional analysis. View our Syphilis Testing Report Overview here: https://www.researchnester.com/reports/syphilis-testing-market/8073

Market Segmentation

The primary and secondary syphilis segment constitutes the highest-demand category and is projected to reach 62% of total market share by 2035. This segment experiences sustained testing volume due to the high transmissibility of early-stage infections, public health surveillance requirements, and guidelines promoting universal screening in high-risk groups. Testing during these stages enables timely treatment with optimal cure rates and significant reduction in disease spread.

Laboratory testing continues to play a dominant role in the Syphilis Testing Market as health systems prioritize accurate, sensitive, and scalable diagnostic approaches. Centralized laboratories, hospital-based diagnostic units, and reference labs increasingly rely on automated treponemal and non-treponemal analyzers, chemiluminescent immunoassays (CLIA), and enzyme immunoassays (EIA). These laboratory platforms enable large-volume screening, high diagnostic precision, and integration with infectious disease surveillance systems.

➤ Discover how the Syphilis Testing Market is evolving globally - access your free sample report →https://www.researchnester.com/sample-request-8073

Top Market Trends

1. Growth of Dual and Multi-Disease Rapid Testing Platforms

The acceleration of dual HIV/syphilis testing is among the most influential trends in the market. Public health agencies increasingly favor dual tests for antenatal screening, STI clinics, and community outreach programs, enabling simultaneous detection of co-infections.

Example: Several global health organizations have shipped millions of dual rapid tests to Asia, Africa, and Latin America in the last 12 months, significantly improving screening efficiency and early detection rates.

2. Expansion of Digital Diagnostics and AI-Enhanced Screening

Digital connectivity and AI-driven diagnostics are reshaping the workflow of syphilis screening. Automated result interpretation, cloud-integrated reporting systems, and AI-supported serology platforms reduce human error and accelerate clinical decision-making.

Example: Diagnostic manufacturers have launched AI-enhanced readers for rapid syphilis assays, allowing standardized interpretation and real-time data reporting to public health authorities.

3. Automation and High-Throughput Laboratory Testing
As national screening rates increase, laboratories are adopting fully automated analyzers capable of processing hundreds to thousands of samples per hour. High-throughput CLIA and immunoassay platforms improve accuracy and reduce turnaround times.

Example: Over the past year, leading diagnostic companies have expanded their automated infectious disease analyzer portfolios to support syphilis screening alongside HIV, hepatitis, and TORCH testing.

➤ Stay ahead of the curve with the latest Syphilis Testing Market trends. Claim your sample report →https://www.researchnester.com/sample-request-8073

Recent Company Developments

Below are notable developments among major companies and high-growth players in the Syphilis Testing Market over the last 12 months:

1. Abbott Laboratories

Abbott expanded its rapid point-of-care syphilis test offerings across emerging markets and strengthened integration of its diagnostics with digital health platforms. The company also released updated clinical guidance tools to support accurate serology interpretation.

2. Siemens Healthineers

Siemens introduced upgraded CLIA-based infectious disease panels with enhanced sensitivity for treponemal antibody detection. The company also expanded its analyzer installations across hospital networks in North America and Europe.

3. Bio-Rad Laboratories

Bio-Rad launched new serology automation technologies targeting syphilis and other sexually transmitted infections. The company also expanded manufacturing capacity to meet rising demand for high-volume diagnostic kits.

4. F. Hoffmann-La Roche (Roche Diagnostics)

Roche expanded the reach of its cobas analyzers, which integrate syphilis screening as part of multiplex infectious disease panels. Recent investments include digital workflow upgrades and expansions in Asia Pacific markets.

5. Thermo Fisher Scientific

Thermo Fisher strengthened its assay portfolio with improved treponemal confirmatory test kits. The company also invested in biologics R&D to streamline next-generation immunodiagnostic development.

➤ Request Free Sample PDF Report @ https://www.researchnester.com/sample-request-8073

➤ Related news:
https://www.linkedin.com/pulse/what-driving-growth-stress-tracking-devices-market-fgglf
https://www.linkedin.com/pulse/how-schizophrenia-drugs-market-evolving-modern-healthcare-sftcf/

Contact Data
AJ Daniel
Corporate Sales, USA
Research Nester
77 Water Street 8th Floor, New York, 10005
Email: info@researchnester.com
USA Phone: +1 646 586 9123
Europe Phone: +44 203 608 5919

About Research Nester
Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

This release was published on openPR.